BiotechTubeBiotechTube
Home/4D Molecular Therapeutics/David Anderson
DA

David Anderson

Communications/Medical Affairs (inferred from author credit)

4D Molecular Therapeutics

Therapeutic Areas

OphthalmologyPulmonologyRare Disease

4D Molecular Therapeutics Pipeline

DrugIndicationPhase
4D-150Wet Age-Related Macular Degeneration (wet AMD)Phase 3
4D-710Cystic Fibrosis (CF) lung diseasePhase 1/2
4D-125X-Linked Retinitis Pigmentosa (XLRP)Phase 1/2

Leadership Team at 4D Molecular Therapeutics

DK
David Kirn
Co-Founder and Chief Executive Officer
RK
Robert Kim
Chief Medical Officer
CK
Christine Kay
MD, Principal Investigator (PRISM trial)
EA
Erik Allison
Communications/Medical Affairs (inferred from author credit)
M
Malina
Corporate Communications/Web Manager (inferred from author credit)
View full 4D Molecular Therapeutics profile